Lymphocyte-predominant Hodgkin disease is a rare form of Hodgkin lymphoma that is recognized as a separate histopathological entity. This disease tends to have multiple relapses, but has an overall good prognosis. Owing to its rarity, and the prolonged time period between recurrence and transformation events, there is no consensus regarding optimal management. However, the National Comprehensive Cancer Network guidelines indicate that for early stages, appropriate treatment is radiotherapy. Several management options have been reported including observation, radiation, chemotherapy, combined chemoradiotherapy, and anti-CD20 antibody therapy. Salvage therapy remains effective in inducing prolonged remission in patients with relapsed/refractory disease.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/COC.0b013e31820dbc2c | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
CD4CD8 double-positive T cells in immune disorders and cancer: Prospects and hurdles in immunotherapy.
Autoimmun Rev
January 2025
Department of Toxicology and Cancer Biology, Collage of Medicine, University of Kentucky, Lexington, KY 40536, USA; Markey Cancer Center, University of Kentucky, Lexington, KY 40536, USA. Electronic address:
CD4 and CD8 T cells play critical roles in both innate and adaptive immune responses, managing and modulating cellular immunity during immune diseases and cancer. Their well-established functions have led to significant clinical benefits. CD4CD8 double-positive (DP) T cells, a subset of the T cell population, have been identified in the blood and peripheral lymphoid tissues across various species.
View Article and Find Full Text PDFNodular lymphocyte-predominant Hodgkin lymphoma revisited: current management strategies and future perspectives.
Leuk Lymphoma
January 2025
First Department of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Dusseldorf, University of Cologne, Cologne, Germany.
Article Synopsis
- Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare type of lymphoma, making up about 5% of Hodgkin lymphoma cases, and shares some characteristics with B-cell non-Hodgkin lymphoma.
- NLPHL is typically diagnosed at early stages and has a slow progression, leading to excellent long-term survival rates for most patients.
- Treatment mainly mirrors classical Hodgkin lymphoma but may include rituximab; future strategies could involve innovative therapies like CAR T-cell therapy and bispecific antibodies.
Exploring the complexity, treatment challenges, and outcomes in pediatric nodular lymphocyte predominant Hodgkin lymphoma: a perspective from a low-middle-income country.
Front Oncol
October 2024
Pediatric Oncology Department, National Cancer Institute, Cairo University, Cairo, Egypt.
Background: In children, nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is an uncommon subtype of Hodgkin lymphoma. Given the lack of data on the best chemotherapy regimen, there is a knowledge gap in best management.
Methods: This retrospective study included all pediatric patients with NLPHL diagnosed and treated at the Children's Cancer Hospital, Egypt (2007-2018).
GATA3 Immunohistochemical Staining in Classical Hodgkin Lymphoma and its Diagnostic Utility in Differential Diagnosis.
Turk J Haematol
October 2024
İstanbul University, İstanbul Faculty of Medicine, Department of Pathology, İstanbul, Türkiye.
Objective: Classical Hodgkin lymphoma (CHL) is a common lymphoid neoplasm with a wide range of differential diagnosis. Although it has a specific immunophenotype, aberrant expression of antigens can cause problems at its diagnosis. In this study we evaluated the usefulness of GATA3 in differential diagnosis of classical Hodgkin lymphoma.
View Article and Find Full Text PDFFlow Cytometry for Non-Hodgkin and Hodgkin Lymphomas.
Methods Mol Biol
October 2024
Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA.
Multiparametric flow cytometry is a powerful diagnostic tool that permits rapid assessment of cellular antigen expression to quickly provide immunophenotypic information suitable for disease classification. This chapter describes a general approach for the identification of abnormal lymphoid populations by flow cytometry, including B, T, NK, and Hodgkin lymphoma cells suitable for the clinical and research environment. Knowledge of the common patterns of antigen expression of normal lymphoid cells is critical to permit identification of abnormal populations at disease presentation and for minimal residual disease assessment.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!